ResoTher Pharma
Denmark - HoltePharmaceutical
Focus: ResoTher Pharma is a private Danish biotech founded in 2022 focused on cardiovascular and metabolic disease treatments. The company is in early-stage development with a single Phase 2 program.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
PRIVATE
Open Jobs
0
About ResoTher Pharma
AI assessmentNot HiringNo open roles listed right now. Follow ResoTher Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 2
Clinical Trials (1)
NCT06465303A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)
Phase 2Help build intelligence for ResoTher Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.